ClinicalTrials.gg
RecruitingNCT07051967Updated Sep 25, 2025

Post-intensive Care Syndromes in Pregnant Patients With Respiratory Failure and COVID-19 Compared to Non-pregnant Patients With Respiratory Failure and COVID-19

An observational study in COVID-19, Acute Respiratory Distress Syndrome Due to COVID-19 and Pregnancy Related, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Charite University, Berlin, Germany · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in COVID-19 by Charite University, Berlin, Germany — 2 open to participants now, 2 under way, none of them phase 3. COVID-19 · Charite University, Berlin, Germany.

Started
2025
the only one that year
Observational
7 of 12
2 open now
Registered
12th of 12
by date

Among the 12 studies in COVID-19 by Charite University, Berlin, Germany, this one is the only one that started in 2025, is one of 7 observational ones, and was the 12th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 12 studies in COVID-19 by Charite University, Berlin, Germany are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in COVID-19 by Charite University, Berlin, Germany, or all of them as a file.
02

Study summary

The aim of this study is to characterize patients in the Post-Intensive-Care-Syndrome (PICS) outpatient clinic based on routine data and to evaluate their treatment outcome over the course of their treatment. For this purpose, data sets from approx. 40 patients who were treated in the intensive care unit subsequently evaluated in the PICS outpatient clinic between March 27, 2020, and May 6, 2024, will be analyzed.

Read the detailed description

This is a retrospective comparison of approximately 13 pregnant patients and approximately 27 non-pregnant patients who developed respiratory failure (also known as acute respiratory distress syndrome, or ARDS) due to COVID-19 infection. The analysis is based on routine treatment data from the Post-Intensive Care Syndrome (PICS) outpatient clinic of the Department of Anesthesiology and Intensive Care Medicine (CCM/CVK), as well as intensive care treatment data, primarily from the Department of Anesthesiology and Intensive Care Medicine (CCM/CVK). In some cases, additional data were obtained from the Medical Clinic for Nephrology and Internal Intensive Care Medicine (CCM/CVK/CBF), the Medical Clinic specializing in Hepatology and Gastroenterology (CCM/CVK), and the Department of Infectiology, Pulmonology, and Intensive Care Medicine (CCM).

03

Conditions studied

  • COVID-19
  • Acute Respiratory Distress Syndrome Due to COVID-19
  • Pregnancy Related

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult female pregnant and non-pregnant patients who were admitted to a Charité intensive care unit and follow-up examination by the Post-Intensive-Care-Syndrome (PICS) outpatient clinic of the Department of Anesthesiology and Intensive Care Medicine, Charité - Universitaetsmedizin Berlin between March 27, 2020 and May 6, 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 years and older
  • Admission to a Charité intensive care unit and follow-up examination by the Post-Intensive-Care-Syndrome (PICS) outpatient clinic of the Department of Anesthesiology and Intensive Care Medicine between March 27, 2020 and May 6, 2024.
  • COVID-19 infection in temporal assocoation with the intensive care unit admission.
  • Intensive care unit admission with lung failure or development of lung failure in the course of intensive care unit treatment.
  • Admission to the intensive care unit with lung failure or development of lung failure during intensive care unit stay.

Exclusion criteria

Exclusion Criteria:

  • Gender: Male
  • Diagnosis: Non-COVID or no respiratory failure
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Female pregnant patients with COVID-19 related Acute respiratory distress syndrome

    * Pregnancy at the time of initial hospital admission (not necessarily at the time of transfer to Charité - Universitätsmedizin Berlin). * Age: 18 years and older * Admission to a Charité intensive care unit and follow-up examination by the Post-Intensive-Care-Syndrome (PICS) outpatient clinic of the Department of Anesthesiology and Intensive Care Medicine between March 27, 2020 and May 6, 2024. * COVID-19 infection in temporal association with the intensive care unit admission. * Intensive care unit admission with lung failure or development of lung failure in the course of intensive care unit treatment. * Admission to the intensive care unit with lung failure or development of lung failure during intensive care unit stay

  • Female non-pregnant patients with COVID-19 related Acute respiratory distress syndrome

    * No pregnancy at the time of admission. * Age: 18 years and older * Admission to a Charité intensive care unit and follow-up examination by the Post-Intensive-Care-Syndrome (PICS) outpatient clinic of the Department of Anesthesiology and Intensive Care Medicine between March 27, 2020 and May 6, 2024. * COVID-19 infection in temporal association with the intensive care unit admission. * Intensive care unit admission with lung failure or development of lung failure in the course of intensive care unit treatment. * Admission to the intensive care unit with lung failure or development of lung failure during intensive care unit stay

06

What researchers measure

Primary outcomes

  1. Impairment in at least one PICS domain (mobility, cognition, and/or mental health)

    Impairment in at least one PICS domain (mobility, cognition, and/or mental health) after discharge from the ICU, assessed at the time of presentation to the PICS outpatient clinic. The planned PICS outpatient presentation takes place 3 and 6 months (ranging from 1 month to 3 years) after the initial ICU stay.

    Time frame: 27.03.2020-06.05.2024

Secondary outcomes

  1. Catecholamine therapy

    Catecholamine therapy during intensive care unit (ICU) treatment is measured in doses and duration.

    Time frame: 27.03.2020-06.05.2024

  2. Extracorporeal Membrane Oxygenation treatment

    Extracorporeal Membrane Oxygenation treatment in the ICU Yes or No

    Time frame: 27.03.2020-06.05.2024

  3. Need for ventilation during ICU treatment

    Need for ventilation during ICU treatment and, if so, ventilation route (non-invasive and invasive, endotracheal tube and tracheostomy tube) and duration of ventilation

    Time frame: 27.03.2020-06.05.2024

  4. Duration of ventilation during ICU treatment

    Duration of ventilation during ICU treatment is measured in hours

    Time frame: 27.03.2020-06.05.2024

  5. Oxygenation index

    Oxygenation index/Horowitz index is defined as the ratio of the arterial partial pressure of oxygen (PaO₂, in mmHg) to the fraction of inspired oxygen (FiO₂, expressed as a decimal).

    Time frame: 27.03.2020-06.05.2024

  6. Severity of illness

    Severity of illness during ICU treatment is assessed with validated intensive care unit scores.

    Time frame: 27.03.2020-06.05.2024

  7. Incidence of delirium

    Incidence of delirium in the ICU is measured with validated delirium scores.

    Time frame: 27.03.2020-06.05.2024

  8. Duration of delirium

    Duration of delirium in the ICU is measured in days

    Time frame: 27.03.2020-06.05.2024

  9. Sedation Medications

    Kind of medications required for sedation.

    Time frame: 27.03.2020-06.05.2024

  10. Sedation dosage

    The amount of drug required for sedation.

    Time frame: 27.03.2020-06.05.2024

  11. Duration of sedation

    Duration of sedation is measured in days.

    Time frame: 27.03.2020-06.05.2024

  12. Depth of sedation

    Depth of sedation during ICU treatment

    Time frame: 27.03.2020-06.05.2024

  13. Continuous muscle relaxation

    Continuous muscle relaxation during ICU treatment

    Time frame: 27.03.2020-06.05.2024

  14. Vaccination status

    Vaccination status at the start of ICU treatment

    Time frame: 27.03.2020-06.05.2024

  15. COVID-19-specific immunotherapy

    COVID-19-specific immunotherapy (e.g., tocilizumab, dexamethasone, baricitinib) during ICU treatment

    Time frame: 27.03.2020-06.05.2024

  16. Type of Anti-infective therapy

    Type of anti-infective therapy during ICU treatment

    Time frame: 27.03.2020-06.05.2024

  17. Duration of Anti-infective therapy

    Duration of anti-infective therapy during ICU treatment is measured in days.

    Time frame: 27.03.2020-06.05.2024

  18. Week of pregnancy

    Week of pregnancy during ICU treatment in the pregnant women group

    Time frame: 27.03.2020-06.05.2024

  19. Need for a cesarean section

    Need for a cesarean section in the pregnant women group, yes or no.

    Time frame: 27.03.2020-06.05.2024

  20. Organ complications

    Organ complications, including bleeding and pregnancy complications during hospital treatment. Data from patient records.

    Time frame: 27.03.2020-06.05.2024

  21. Nutrition

    Nutrition (enteral vs. parenteral) during ICU treatment

    Time frame: 27.03.2020-06.05.2024

  22. Dialysis 1

    Dialysis during ICU treatment (binary)

    Time frame: 27.03.2020-06.05.2024

  23. Dialysis 2

    Dialysis during ICU treatment (duration)

    Time frame: 27.03.2020-06.05.2024

  24. Intensive care unit mortality

    Data from patient records

    Time frame: 27.03.2020-06.05.2024

  25. Hospital mortality

    Data from patient records

    Time frame: 27.03.2020-06.05.2024

  26. 90-day mortality

    Data from patient records

    Time frame: 27.03.2020-06.05.2024

  27. 180-day mortality

    Data from patient records

    Time frame: 27.03.2020-06.05.2024

  28. Intensive care unit length of stay

    Participants are followed up for the duration of intensive care unit stay, an expected average of 2 days

    Time frame: 27.03.2020-06.05.2024

  29. Duration of Hospital stay

    Participants are followed up for the duration of hospital stay, an expected average of 7 days

    Time frame: 27.03.2020-06.05.2024

  30. Grip strength Test

    Grip strength at the time of presentation to the PICS outpatient clinic is measured with a dynamometer.

    Time frame: 27.03.2020-06.05.2024

  31. Mobility

    Mobility at the time of presentation to the PICS outpatient clinic is measured with the Timed Up-and-Go (TUG).

    Time frame: 27.03.2020-06.05.2024

  32. Cognition 1

    Cognition 1 at the time of presentation to the PICS outpatient clinic is measured with the MiniCog. The MiniCog consists of two items, the word recall test and the clock-drawing test. Performance in these test is rated on a scale ranging from 0 - 5, with \<3 points indicating a suspicion of dementia.

    Time frame: 27.03.2020-06.05.2024

  33. Cognition 2

    Cognition 2 at the time of presentation to the PICS outpatient clinic is measured with the Animal Naming Test

    Time frame: 27.03.2020-06.05.2024

  34. Mental health

    Mental health at the time of presentation to the PICS outpatient clinic is measured with Patient Health Questionnaire-4 (It comprises the first two questions of the depression module of the PHQ-D \[PHQ-2\] and the first two questions of the module for assessing generalized anxiety \[GAD-2\]) and patient questionnaire with subjective patient assessment.

    Time frame: 27.03.2020-06.05.2024

  35. PBQ Parent-Child Relationship Questionnaire

    PBQ at the time of presentation to the PICS outpatient clinic. This questionnaire is a 25-question self-completion questionnaire, which was developed in order to recognize disorders in the mother-child relationship at an early stage. The questionnaire is made up of 4 scales. Scale 1 Delayed attachment cut-off 12, Scale 2 Rejection and anger cut-off 17, Scale 3 Anxiety cut-off 10 and Scale 4 Risk of child abuse cut-off 3.

    Time frame: 27.03.2020-06.05.2024

  36. Edinburgh Postpartum Depression Questionnaire (EPDS)

    The Edinburgh Postnatal Depression Scale (EDPS) was developed to identify women who may have postpartum depression. Each answer is given a score of 0 to 3 .The maximum score is 30. A score of more than 10 suggests minor or major depression may be present.

    Time frame: 27.03.2020-06.05.2024

  37. Health-related quality of life

    Health-related quality of life at the time of presentation to the PICS outpatient clinic is measured with EQ-5D-5L questionnaire. Higher Score indicate better Healt-related quality of life.

    Time frame: 27.03.2020-06.05.2024

07

Study locations

1 of 1 sites recruiting
  • Department of Anesthesiology and Intensive Care Medicine (CCM/CVK), Charité - Universitätsmedizin Berlin
    Berlin, 13353, Germany
    Recruiting
    • Claudia Spies, MD. Prof. · Contactclaudia.spies@charite.de · +49 30 450 55 11 02
    • Claudia Spies, MD, Prof. · Principal investigator
    • Karin Steinecke, MD · Sub investigator
    • Nicolas Paul, MD · Sub investigator
    • Sonya Arustamyan, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jun 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 4, 2025
StartActual
Sep 22, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07051967
Responsible party
Claudia Spies (Head of the Department of Anesthesiology and Intensive Care Medicine (CCM/CVK), Charité - Universitaetsmedizin Berlin, Charite University, Berlin, Germany) — Principal investigator
First posted
Jul 4, 2025
Start date
Sep 22, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Sep 25, 2025

Study contacts

Claudia Spies, MD Prof.
Contact
claudia.spies@charite.de
+49 30 450 551102
Claudia Spies, MD, Prof.
study director · Charite University, Berlin, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion